Posted by Michael Wonder on 24 Oct 2024
HiberCell receives FDA fast track designation for HC-7366 for the treatment of relapsed or refractory acute myeloid leukaemia
23 October 2024 - HiberCell is pleased to announce that the US FDA has granted fast track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia.
HC-7366 is currently under clinical investigation in both solid and liquid tumour settings.
